Concepedia

Bellinda L. King‐Kallimanis

BL

55

Publications

3.1K

Citations

29

H-Index

2007

Active since

Affiliations

United States Food and Drug Administration(Current)

Trinity College Dublin

Center for Drug Evaluation and Research

University of Amsterdam

University of South Florida

Bellinda L. King‐Kallimanis is an author at United States Food and Drug Administration specializing in medicine, geriatrics, and psychiatry.

ORCID

Top concepts

Publications per year

2007–2024

55

Publications

55

Prevalence of Mood, Anxiety, and Substance-Abuse Disorders for Older Americans in the National Comorbidity Survey-Replication

Amber M. Gum, Bellinda L. King‐Kallimanis, Robert Kohn · American Journal of Geriatric Psychiatry · 2009 · 352 citations

, , +14

Screening and Brief Intervention for Substance Misuse Among Older Adults: The Florida BRITE Project

Lawrence Schonfeld, Bellinda L. King‐Kallimanis, Darran M. Duchene et al. · American Journal of Public Health · 2009 · 196 citations · Full text

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Preeti Narayan, Sakar Wahby, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 164 citations

, , +17

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan, Tatiana M. Prowell, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 157 citations · Full text

Negative perceptions of aging predict longitudinal decline in cognitive function.

Deirdre A. Robertson, Bellinda L. King‐Kallimanis, Rose Anne Kenny · Psychology and Aging · 2015 · 139 citations

, , +14

Rows per page

1–5 of 55